FML-S by AbbVie is clinical pharmacology corticosteroids suppress the inflammatory response to a variety of agents and they probably delay or slow healing. Approved for inflammatory conditions of the palpebral, bulbar conjunctiva, cornea and 8 more indications. First approved in 1989.
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
FML-S is a fixed-dose ophthalmic suspension combining fluorometholone (a corticosteroid) and sulfacetamide sodium (an antimicrobial) for treating inflammatory eye conditions. It suppresses inflammatory response while providing antimicrobial coverage against susceptible bacteria, making it suitable for conditions where infection risk is a concern. The corticosteroid component inhibits edema, capillary dilation, leukocyte migration, and scar formation associated with ocular inflammation.
As an approaching LOE product, FML-S brand team faces revenue compression and likely smaller team resources focused on retention and cost management.
CLINICAL PHARMACOLOGY Corticosteroids suppress the inflammatory response to a variety of agents and they probably delay or slow healing. They inhibit the edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and…
Worked on FML-S at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
FML-S offers limited career growth due to its LOE-approaching status and minimal linked job openings; roles on this product focus on customer retention, competitive pricing, and managed care negotiations rather than new product launches or innovation. Professionals seeking dynamic career development should consider it a stabilizing assignment rather than a growth opportunity.